| 0.67 0.001 (0.15%) | 06-20 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 0.88 | 1-year : | 0.98 |
| Resists | First : | 0.75 | Second : | 0.83 |
| Pivot price | 0.74 |
|||
| Supports | First : | 0.62 | Second : | 0.52 |
| MAs | MA(5) : | 0.69 |
MA(20) : | 0.73 |
| MA(100) : | 0.75 |
MA(250) : | 1.05 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 11.2 |
D(3) : | 23.9 |
| RSI | RSI(14): 44.2  |
|||
| 52-week | High : | 1.7 | Low : | 0.44 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACET ] has closed above bottom band by 8.6%. Bollinger Bands are 20.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.68 - 0.68 | 0.68 - 0.69 |
| Low: | 0.65 - 0.65 | 0.65 - 0.66 |
| Close: | 0.66 - 0.67 | 0.67 - 0.68 |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Mon, 26 May 2025
Adicet Bio’s SWOT analysis: gamma-delta T cell therapy stock faces pivotal year - Investing.com
Fri, 09 May 2025
Adicet Bio (ACET) Upgraded to Buy: Here's What You Should Know - Nasdaq
Wed, 07 May 2025
Adicet Bio Reports Q1 2025 Results and Updates - TipRanks
Tue, 06 May 2025
Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates - Business Wire
Sun, 27 Apr 2025
We're Keeping An Eye On Adicet Bio's (NASDAQ:ACET) Cash Burn Rate - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 83 (M) |
| Shares Float | 61 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 67.6 (%) |
| Shares Short | 2,370 (K) |
| Shares Short P.Month | 2,060 (K) |
| EPS | -1.29 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.95 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.7 % |
| Return on Equity (ttm) | -55.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -95 (M) |
| Levered Free Cash Flow | -56 (M) |
| PE Ratio | -0.52 |
| PEG Ratio | 0 |
| Price to Book value | 0.34 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|